1. Medtech Insight

US Could Lose Its First Approver Advantage After FDA Layoffs

 
• By Sarah Karlin-Smith, Elizabeth Orr, and Derrick Gingery

Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.

Dominoes falling in the dark
• Source: Shutterstock

The speed of US medical product reviews likely will be slowed by the approximately 3,500 US Food and Drug Administration job cuts made 1 April, which experts expect will propel drug and medical device developers to obtain product approvals in other parts of the world, such as Europe, first.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medtech Insight

More from Regulation